Tutorials
XBRU:HYL (Belgium)  
Hyloris Pharmaceuticals SA logo

Hyloris Pharmaceuticals SA

€ 13.98 (+1.9%) Aug 12
P/E:
At Loss
P/B:
8.14
Market Cap:
€ 391.44M ($ 401.76M)
Enterprise V:
€ 353.19M ($ 362.50M)
Volume:
2.71K
Avg Vol (2M):
3.77K
Also Trade In:
Volume:
2.71K
Market Cap €:
391.44M
Market Cap $:
401.76M
PE Ratio:
At Loss
Avg Vol (2-Month):
3.77K
Enterprise Value €:
353.19M
Enterprise Value $:
362.50M
PB Ratio:
8.14
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Hyloris Pharmaceuticals SA
Boulevard Gustave-Kleyer 17, Liege, BEL, 4000
Description
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans three areas of focus IV Cardiovascular, Other Reformulations, and Established Market (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain. It has 12 product candidates in various stages of development.
Name Current Vs Industry Vs History
Cash-To-Debt 4.11
Equity-to-Asset 0.76
Debt-to-Equity 0.26
Debt-to-EBITDA -1.16
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 14.3
Distress
Grey
Safe
Beneish M-Score 14.62
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 52.08
9-Day RSI 48.63
14-Day RSI 47.56
6-1 Month Momentum % -13.85
12-1 Month Momentum % -5.02

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.6
Quick Ratio 3.6
Cash Ratio 3.37
Days Sales Outstanding 112.63
Days Payable 5814.98

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5.9

Financials (Next Earnings Date:2022-08-31 Est.)

XBRU:HYL's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 3.096
EPS (TTM) (€) -0.45
Beta 0
Volatility % 28.47
14-Day RSI 47.56
14-Day ATR (€) 0.495561
20-Day SMA (€) 14.23
12-1 Month Momentum % -5.02
52-Week Range (€) 12.7 - 19.1
Shares Outstanding (Mil) 28

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Hyloris Pharmaceuticals SA Filings

Document Form Filing Date
No Filing Data